Get the Stockscreener App
1.18
2.48%
-0.03
After Hours:
1.22
0.04
+3.39%
Pds Biotechnology Corporation stock is traded at $1.18, with a volume of 238.59K.
It is down -2.48% in the last 24 hours and down -21.85% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
238.59K
Relative Volume:
0.48
Market Cap:
$53.94M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.0085
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+2.61%
1M Performance:
-21.85%
6M Performance:
-23.87%
1Y Performance:
-70.05%
1-Day Range:
$1.15
$1.2296
1-Week Range:
$1.12
$1.2691
52-Week Range:
$0.8505
$4.29
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.18 | 55.31M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
What analysts say about PDS Biotechnology Corporation stockOutstanding trading profits - PrintWeekIndia
What makes PDS Biotechnology Corporation stock price move sharplyReal Time Alert Service - Newser
Is PDS Biotechnology Corporation stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com
PDS Biotechnology Corporation Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - MSN
What drives PDS Biotechnology Corporation stock priceFree Stock Movement Tracking - jammulinksnews.com
Is PDS Biotechnology Corporation a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
How PDS Biotechnology Corporation stock performs during market volatilityHigh Yield Stock Selection - Newser
Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Stock Market Knowledge Sharing - Newser
PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria - Investing.com Nigeria
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial - Yahoo Finance
PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - MarketScreener
PDS Biotechnology stock rises after trial meets criteria for expansion By Investing.com - Investing.com Nigeria
PDS Biotechnology stock rises after trial meets criteria for expansion - Investing.com Australia
PDS Biotech's PDS01ADC: A Breakthrough in Cytokine Therapy for Metastatic Colorectal Cancer - AInvest
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - The Manila Times
PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results - Stock Titan
PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB Stock News - GuruFocus
PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener
PDS Biotechnology holds a conference call - TipRanks
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World
HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):